Valdecoxib Recovers the Lipid Composition, Order and Dynamics in Colon Cancer Cell Lines Independent of COX-2 Expression: An ATR-FTIR Spectroscopy Study

• Published in: Applied spectroscopy Vol. 71; no. 1; p. 105
• Main Authors: Inan Genç, Aysun, Gok, Seher, Banerjee, Sreeparna, Severcan, Feride
• Format: Journal Article
• Language: English
• Published: United States 01.01.2017
• Subjects: Alkenes - analysis; Alkenes - chemistry; Antineoplastic Agents - pharmacology; Antineoplastic Agents - toxicity; Cell Line, Tumor; Cell Survival - drug effects; Cluster Analysis; Colonic Neoplasms - metabolism; Cyclooxygenase 2 Inhibitors - pharmacology; Cyclooxygenase 2 Inhibitors - toxicity; HT29 Cells; Humans; Isoxazoles - pharmacology; Isoxazoles - toxicity; Spectroscopy, Fourier Transform Infrared - methods; Sulfonamides - pharmacology; Sulfonamides - toxicity; ATR-FT-IR spectroscopy; attenuated total reflection infrared spectroscopy; COX-2 inhibitors; HT29; Colon cancer; valdecoxib; SW620
• ISSN: 1943-3530
• DOI: 10.1177/0003702816654164

Prostanoids play an important role in a variety of physiological and pathophysiological processes including inflammation and cancer. The rate-limiting step in the prostanoid biosynthesis pathway is catalyzed by cyclooxygenases (COXs). Aberrant expression of the inducible isoform COX-2 plays a significant role in colon cancer initiation and progression. In this study, we have hypothesized that COX-2 specific inhibitors such as Valdecoxib (VLX), being highly hydrophobic, may alter biophysical properties of cellular lipids. In this study, COX-2 expressing (HT29) and COX-2 non-expressing (SW620) colon cancer cell lines were treated with VLX and examined using attenuated total reflection infrared spectroscopy. The results revealed that VLX treatment decreased lipid fluidity in the cells irrespective of COX-2 expression status and affected order parameters of the lipids in both cell lines. Cluster analysis also indicated that the spectral differences between the two cell lines are profound and could be successfully differentiated. Valdecoxib treatment could enhance the composition, order and dynamics of the lipids of colon cancer cells independently of its COX-2 inhibitory mechanism. Valdecoxib has therapeutic effects upon colon cancer, therefore it can be used as an adjuvant and/or chemopreventive agent for colon cancer.